Search

The author presents case studies in dyslipidaemia and the use of lipid-lowering drugs among patients at high risk of a cardiovascular event. Therapies in line with the current guidance from Great Britain's National Institute for Health and Clinical Excellence are suggested. The author stresses that decisions regarding lipid management and cardiovascular disease risk reduction must be made with the individual patient and after careful appraisal of the risks, benefits, and available alternatives.

The article discusses various issues concerning lipid modification in relation to cardiovascular disease (CVD). It cites the guidance on lipid modification published by Great Britain National Institute for Clinical Excellence (NICE). An explanation on the value of lipid modification in the primary prevention of CVD is offered, along with the factors that affect cholesterol measurement. The article also discusses the pharmacological management of CVD.

Focuses on lipid lowering treatment for type 2 diabetics. Risk of developing a first cardiac event in patients; Criteria that must be met by patients to participate in the Collaborative Atorvastatin in Diabetes Study; Effectiveness of atorvastatin with placebo for reducing the risk of coronary heart disease.

The article reports that practice nurses in Great Britain will be expected to hit tough new targets on the identification of people at risk of cardiovascular disease (CVD) and for lipid modification, following the publication of new guidance from the National Institute for Clinical Excellence (NICE). NICE says that practices must adopt a more systematic strategy to identify people who are likely to be at high risk of CVD.